a1 Professor, Epidemiology, Biostatistics & HTA, Head of HTA section, Radboud University Medical Centre, P.O. Box 9101, 6500HB Nijmegen, The Netherlands Email: email@example.com
One of the key tasks of governments and their advisory bodies is to decide what the nature and quality of the evidence should be which they use to support their policies. Evidence, as pointed out by Valerie Miké, is inherently incomplete, provisional, and subject to refutation (4). So when are we justified to presume sufficient value of a healthcare technology, warranting its public provision and funding?